{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:45:20Z","timestamp":1782229520294,"version":"3.54.5"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002349","name":"Academy of Scientific Research and Technology","doi-asserted-by":"publisher","award":["\u201c\"Apply your idea\" program \u201cproject ID: 7303, To M.A.\u201d"],"award-info":[{"award-number":["\u201c\"Apply your idea\" program \u201cproject ID: 7303, To M.A.\u201d"]}],"id":[{"id":"10.13039\/501100002349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Genetic Engineering and Biotechnology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1186\/s43141-020-00055-5","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T05:03:35Z","timestamp":1595912615000},"page":"35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6554-4250","authenticated-orcid":false,"given":"Dina B.","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zayyanu","family":"Shitu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1186\/s43141-020-00055-5_bib1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Research."},{"key":"10.1186\/s43141-020-00055-5_bib2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan","volume":"395","author":"Huang","year":"2020","journal-title":"China. Lancet."},{"key":"10.1186\/s43141-020-00055-5_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol Biol."},{"key":"10.1186\/s43141-020-00055-5_bib4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet."},{"key":"10.1186\/s43141-020-00055-5_bib5","unstructured":"WHO. WHO Coronavirus Disease (COVID-19) Dashboard. 2020."},{"key":"10.1186\/s43141-020-00055-5_bib6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","article-title":"Broad spectrum antiviral agent niclosamide and its therapeutic potential","volume":"6","author":"Xu","year":"2020","journal-title":"ACS Infectious Diseases."},{"key":"10.1186\/s43141-020-00055-5_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nature reviews Drug discovery."},{"key":"10.1186\/s43141-020-00055-5_bib8","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(02)11401-2","article-title":"Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial","volume":"360","author":"Amadi","year":"2002","journal-title":"Lancet."},{"key":"10.1186\/s43141-020-00055-5_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antiviral research."},{"key":"10.1186\/s43141-020-00055-5_bib10","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1021\/jm9010719","article-title":"Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance","volume":"52","author":"de Carvalho","year":"2009","journal-title":"Journal of medicinal chemistry."},{"key":"10.1186\/s43141-020-00055-5_bib11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2217\/17460913.3.5.539","article-title":"Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C","volume":"3","author":"Rossignol","year":"2008","journal-title":"Future microbiology."},{"key":"10.1186\/s43141-020-00055-5_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2014.11.010","article-title":"A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs","volume":"114","author":"Cao","year":"2015","journal-title":"Antiviral research."},{"key":"10.1186\/s43141-020-00055-5_bib13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jinf.2011.08.002","article-title":"Norovirus gastroenteritis successfully treated with nitazoxanide","volume":"63","author":"Siddiq","year":"2011","journal-title":"J Infect."},{"key":"10.1186\/s43141-020-00055-5_bib14","doi-asserted-by":"crossref","first-page":"e00707","DOI":"10.1128\/AAC.00707-18","article-title":"Nitazoxanide inhibits human norovirus replication and synergizes with ribavirin by activation of cellular antiviral response","volume":"62","author":"Dang","year":"2018","journal-title":"Antimicrobial agents and chemotherapy."},{"key":"10.1186\/s43141-020-00055-5_bib15","doi-asserted-by":"crossref","unstructured":"Esquer Garrigos Z, Barth D, Hamdi AM, Abu Saleh OM, Sohail MR (2018) Nitazoxanide Is a Therapeutic Option for Adenovirus-Related Enteritis in Immunocompromised Adults. Antimicrobial agents and chemotherapy. 62","DOI":"10.1128\/AAC.01937-18"},{"key":"10.1186\/s43141-020-00055-5_bib16","doi-asserted-by":"crossref","first-page":"10425","DOI":"10.1038\/s41598-018-28172-9","article-title":"Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57","volume":"8","author":"Piacentini","year":"2018","journal-title":"Sci Rep."},{"key":"10.1186\/s43141-020-00055-5_bib17","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.isci.2019.07.003","article-title":"The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus","volume":"19","author":"Jasenosky","year":"2019","journal-title":"iScience"},{"key":"10.1186\/s43141-020-00055-5_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2007.08.005","article-title":"Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication","volume":"77","author":"Korba","year":"2008","journal-title":"Antiviral research."},{"key":"10.1186\/s43141-020-00055-5_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.antiviral.2016.10.003","article-title":"Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission","volume":"135","author":"Wang","year":"2016","journal-title":"Antiviral research."},{"key":"10.1186\/s43141-020-00055-5_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2017.09.019","article-title":"Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency","volume":"147","author":"Perelygina","year":"2017","journal-title":"Antiviral research."},{"key":"10.1186\/s43141-020-00055-5_bib21","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.virol.2018.03.023","article-title":"Inhibition of vaccinia virus replication by nitazoxanide","volume":"518","author":"Hickson","year":"2018","journal-title":"Virology."},{"key":"10.1186\/s43141-020-00055-5_bib22","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nbt.2391","article-title":"Systematic identification of synergistic drug pairs targeting HIV","volume":"30","author":"Tan","year":"2012","journal-title":"Nature biotechnology."},{"key":"10.1186\/s43141-020-00055-5_bib23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chembiol.2015.12.012","article-title":"Drug Repurposing approach identifies inhibitors of the prototypic viral transcription factor IE2 that block human cytomegalovirus replication","volume":"23","author":"Mercorelli","year":"2016","journal-title":"Cell chemical biology."},{"key":"10.1186\/s43141-020-00055-5_bib24","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2741\/4630","article-title":"Drug repurposing approaches to fight Dengue virus infection and related diseases","volume":"23","author":"Botta","year":"2018","journal-title":"Frontiers in bioscience (Landmark edition)"},{"key":"10.1186\/s43141-020-00055-5_bib25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1743-422X-11-10","article-title":"Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model","volume":"11","author":"Shi","year":"2014","journal-title":"Virology journal."},{"key":"10.1186\/s43141-020-00055-5_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104874","article-title":"Nitazoxanide\/azithromycin combination for COVID-19: a suggested new protocol for early management","volume":"157","author":"Kelleni","year":"2020","journal-title":"Pharmacological Research."},{"key":"10.1186\/s43141-020-00055-5_bib27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S2055-6640(20)30017-0","article-title":"Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19","volume":"6","author":"Pepperrell","year":"2020","journal-title":"J Virus Erad."},{"key":"10.1186\/s43141-020-00055-5_bib28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.5414\/CPP38387","article-title":"Nitazoxanide: pharmacokinetics and metabolism in man","volume":"38","author":"Broekhuysen","year":"2000","journal-title":"International journal of clinical pharmacology and therapeutics."},{"key":"10.1186\/s43141-020-00055-5_bib29","doi-asserted-by":"crossref","unstructured":"Duszynski DW, Kvi\u010derov\u00e1 J, Seville RS. Chapter 18 - Treatment and drug therapies of coccidiosis in carnivora. In: Duszynski DW, Kvi\u010derov\u00e1 J, Seville RS, editors. The Biology and Identification of the Coccidia (Apicomplexa) of Carnivores of the World: Academic Press; 2018. p. 445-63.","DOI":"10.1016\/B978-0-12-811349-3.00018-9"},{"key":"10.1186\/s43141-020-00055-5_bib30","doi-asserted-by":"crossref","first-page":"851","DOI":"10.4155\/fmc-2017-0217","article-title":"Second-generation nitazoxanide derivatives: thiazolides are effective inhibitors of the influenza A virus","volume":"10","author":"Stachulski","year":"2018","journal-title":"Future medicinal chemistry."},{"key":"10.1186\/s43141-020-00055-5_bib31","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1007\/s00018-014-1615-2","article-title":"Antiviral strategies against influenza virus: towards new therapeutic approaches","volume":"71","author":"Loregian","year":"2014","journal-title":"Cellular and molecular life sciences: CMLS."},{"key":"10.1186\/s43141-020-00055-5_bib32","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1128\/AAC.03947-14","article-title":"Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro","volume":"59","author":"Belardo","year":"2015","journal-title":"Antimicrobial agents and chemotherapy."},{"key":"10.1186\/s43141-020-00055-5_bib33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.antiviral.2017.10.002","article-title":"The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide","volume":"147","author":"Tilmanis","year":"2017","journal-title":"Antiviral research."},{"key":"10.1186\/s43141-020-00055-5_bib34","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","article-title":"Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b\/3 trial","volume":"14","author":"Haffizulla","year":"2014","journal-title":"The Lancet Infectious diseases."},{"key":"10.1186\/s43141-020-00055-5_bib35","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1007\/s12098-010-0268-x","article-title":"Nitazoxanide use in rota viral diarrhea. Cure or controversy?","volume":"77","author":"Arun Babu","year":"2010","journal-title":"The Indian Journal of Pediatrics"},{"key":"10.1186\/s43141-020-00055-5_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.15171\/ijtmgh.2017.22","article-title":"Activity of nitazoxanide against viral gastroenteritis: a systematic review","volume":"5","author":"Tan","year":"2017","journal-title":"International Journal of Travel Medicine and Global Health."},{"key":"10.1186\/s43141-020-00055-5_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(06)68852-1","article-title":"Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial","volume":"368","author":"Rossignol","year":"2006","journal-title":"Lancet."},{"key":"10.1186\/s43141-020-00055-5_bib38","first-page":"518","article-title":"Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children","volume":"13","author":"Teran","year":"2009","journal-title":"International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases"},{"key":"10.1186\/s43141-020-00055-5_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001999","article-title":"The vast and varied global burden of norovirus: prospects for prevention and control","volume":"13","author":"Lopman","year":"2016","journal-title":"PLoS medicine."},{"key":"10.1186\/s43141-020-00055-5_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2016.12.010","article-title":"Chronic norovirus infection among solid organ recipients in a tertiary care hospital, the Netherlands, 2006-2014","volume":"23","author":"van Beek","year":"2017","journal-title":"Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"key":"10.1186\/s43141-020-00055-5_bib41","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/j.1365-2036.2006.03128.x","article-title":"Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial","volume":"24","author":"Rossignol","year":"2006","journal-title":"Alimentary pharmacology & therapeutics."},{"key":"10.1186\/s43141-020-00055-5_bib42","first-page":"S255","article-title":"Nitazoxanide is effective therapy for norovirus gastroenteritis after chemotherapy and hematopoietic stem cell transplantation (HSCT)","volume":"21","author":"Morris","year":"2015","journal-title":"Biology of Blood and Marrow Transplantation."},{"key":"10.1186\/s43141-020-00055-5_bib43","doi-asserted-by":"crossref","unstructured":"Hargest V, Sharp B, Livingston B, Cortez V, Schultz-Cherry S (2020) Astrovirus replication is inhibited by nitazoxanide in vitro and in vivo. J Virol. 94","DOI":"10.1128\/JVI.01706-19"},{"key":"10.1186\/s43141-020-00055-5_bib44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jcv.2016.07.004","article-title":"Novel human astroviruses: novel human diseases?","volume":"82","author":"Vu","year":"2016","journal-title":"Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology."},{"key":"10.1186\/s43141-020-00055-5_bib45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1297-9716-42-100","article-title":"Viruses in reptiles","volume":"42","author":"Ariel","year":"2011","journal-title":"Vet Res"},{"key":"10.1186\/s43141-020-00055-5_bib46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12985-020-1279-5","article-title":"Investigations into the presence of nidoviruses in pythons","volume":"17","author":"Blahak","year":"2020","journal-title":"Virology journal"},{"key":"10.1186\/s43141-020-00055-5_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.antiviral.2011.05.017","article-title":"Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells","volume":"91","author":"Yon","year":"2011","journal-title":"Antiviral research."},{"key":"10.1186\/s43141-020-00055-5_bib48","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.gastro.2008.11.037","article-title":"Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin","volume":"136","author":"Rossignol","year":"2009","journal-title":"Gastroenterology."},{"key":"10.1186\/s43141-020-00055-5_bib49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijms.3.47","article-title":"The natural history of hepatitis C virus (HCV) infection","volume":"3","author":"Chen","year":"2006","journal-title":"Int J Med Sci."},{"key":"10.1186\/s43141-020-00055-5_bib50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jcmgh.2018.10.010","article-title":"Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx-DDB1 interaction","volume":"7","author":"Sekiba","year":"2019","journal-title":"Cellular and molecular gastroenterology and hepatology."},{"key":"10.1186\/s43141-020-00055-5_bib51","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/hep4.1339","article-title":"A pilot clinical trial of nitazoxanide in the treatment of chronic hepatitis B","volume":"3","author":"Rossignol","year":"2019","journal-title":"Hepatology Communications."},{"key":"10.1186\/s43141-020-00055-5_bib52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2015.04.016","article-title":"Chikungunya: evolutionary history and recent epidemic spread","volume":"120","author":"Weaver","year":"2015","journal-title":"Antiviral research."},{"key":"10.1186\/s43141-020-00055-5_bib53","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1086\/605496","article-title":"Chikungunya fever: an epidemiological review of a re-emerging infectious disease","volume":"49","author":"Staples","year":"2009","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America."},{"key":"10.1186\/s43141-020-00055-5_bib54","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nature09555","article-title":"Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography","volume":"468","author":"Voss","year":"2010","journal-title":"Nature."},{"key":"10.1186\/s43141-020-00055-5_bib55","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.3390\/v7072792","article-title":"Early Events in chikungunya virus infection-from virus cell binding to membrane fusion","volume":"7","author":"van Duijl-Richter","year":"2015","journal-title":"Viruses."},{"key":"10.1186\/s43141-020-00055-5_bib56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0883073812469443","article-title":"Childhood rubella encephalitis: diagnosis, management, and outcome","volume":"29","author":"Chaari","year":"2014","journal-title":"Journal of child neurology."},{"key":"10.1186\/s43141-020-00055-5_bib57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-virology-031413-085442","article-title":"Oncolytic poxviruses","volume":"1","author":"Chan","year":"2014","journal-title":"Annu Rev Virol."},{"key":"10.1186\/s43141-020-00055-5_bib58","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.antiviral.2009.10.016","article-title":"Understanding and managing the adverse effects of antiretroviral therapy","volume":"85","author":"Hawkins","year":"2010","journal-title":"Antiviral research."},{"key":"10.1186\/s43141-020-00055-5_bib59","series-title":"Human cytomegaloviruses: methods and protocols","first-page":"15","article-title":"Overview of human cytomegalovirus pathogenesis","author":"Nogalski","year":"2014"},{"key":"10.1186\/s43141-020-00055-5_bib60","doi-asserted-by":"crossref","first-page":"155.21","DOI":"10.4049\/jimmunol.186.Supp.155.21","article-title":"The anti-infective nitazoxanide shows strong immumodulating effects (155.21). The","volume":"186","author":"Clerici","year":"2011","journal-title":"Journal of Immunology."},{"key":"10.1186\/s43141-020-00055-5_bib61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.intimp.2012.03.002","article-title":"Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice","volume":"13","author":"Hong","year":"2012","journal-title":"International Immunopharmacology."},{"key":"10.1186\/s43141-020-00055-5_bib62","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet."},{"key":"10.1186\/s43141-020-00055-5_bib63","doi-asserted-by":"crossref","unstructured":"Miner K, Labitzke K, Liu B, Wang P, Henckels K, Gaida K et al (2019) Drug repurposing: the anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways. Frontiers in Pharmacology. 10","DOI":"10.3389\/fphar.2019.00051"},{"key":"10.1186\/s43141-020-00055-5_bib64","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/1570163814666170727130003","article-title":"Update on nitazoxanide: a multifunctional chemotherapeutic agent","volume":"15","author":"Shakya","year":"2018","journal-title":"Current drug discovery technologies."},{"key":"10.1186\/s43141-020-00055-5_bib65","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/irv.12446","article-title":"Influenza antivirals currently in late-phase clinical trial","volume":"11","author":"Koszalka","year":"2017","journal-title":"Influenza and other respiratory viruses."},{"key":"10.1186\/s43141-020-00055-5_bib66","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.clinthera.2009.08.004","article-title":"Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: an open-label, randomized, two-period crossover comparison in healthy Mexican volunteers","volume":"31","author":"Galan-Herrera","year":"2009","journal-title":"Clinical therapeutics."},{"key":"10.1186\/s43141-020-00055-5_bib67","doi-asserted-by":"crossref","unstructured":"Balderas-Acata JI, R\u00edos-Rogr\u00edguezBueno EP, P\u00e9rez-Becerril F, Espinosa-Mart\u00ednez C, Fraga VB, Parra MG-dl. Bioavailability of two oral-suspension formulations of a single dose of nitazoxanide 500 mg: an open-label, randomized-sequence, two-period crossover, comparison in healthy fasted Mexican adult volunteers. 2011.","DOI":"10.4172\/jbb.1000056"},{"key":"10.1186\/s43141-020-00055-5_bib68","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5414\/CPP40213","article-title":"Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses","volume":"40","author":"Stockis","year":"2002","journal-title":"International journal of clinical pharmacology and therapeutics."},{"key":"10.1186\/s43141-020-00055-5_bib69","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan","volume":"323","author":"Wang","year":"2020","journal-title":"China. JAMA."},{"key":"10.1186\/s43141-020-00055-5_bib70","doi-asserted-by":"crossref","unstructured":"Wu R, Wang L, Kuo H-CD, Shannar A, Peter R, Chou PJ et al (2020) An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep.:1\u201315","DOI":"10.1007\/s40495-020-00216-7"},{"key":"10.1186\/s43141-020-00055-5_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral research."},{"key":"10.1186\/s43141-020-00055-5_bib72","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/bjd.18369","article-title":"Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study","volume":"182","author":"Levy","year":"2020","journal-title":"The British journal of dermatology."},{"key":"10.1186\/s43141-020-00055-5_bib73","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4103\/0019-5154.193659","article-title":"Safety of topical medications for scabies and lice in pregnancy","volume":"61","author":"Patel","year":"2016","journal-title":"Indian J Dermatol."},{"key":"10.1186\/s43141-020-00055-5_bib74","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/jac\/dkaa114","article-title":"COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression","volume":"75","author":"Zhou","year":"2020","journal-title":"Journal of Antimicrobial Chemotherapy."},{"key":"10.1186\/s43141-020-00055-5_bib75","unstructured":"FDA. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. 2020."},{"key":"10.1186\/s43141-020-00055-5_bib76","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S2055-6640(20)30018-2","article-title":"Minimum costs to manufacture new treatments for COVID-19","volume":"6","author":"Hill","year":"2020","journal-title":"J Virus Erad."},{"key":"10.1186\/s43141-020-00055-5_bib77","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/zph.12078","article-title":"A survey of U.S. obstetrician-gynecologists\u2019 clinical and epidemiological knowledge of cryptosporidiosis in pregnancy","volume":"61","author":"Domjahn","year":"2014","journal-title":"Zoonoses and public health"}],"container-title":["Journal of Genetic Engineering and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43141-020-00055-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43141-020-00055-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687157X23005644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687157X23005644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43141-020-00055-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:40:17Z","timestamp":1761658817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1687157X23005644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1687157X23005644"],"URL":"https:\/\/doi.org\/10.1186\/s43141-020-00055-5","relation":{},"ISSN":["1687-157X"],"issn-type":[{"value":"1687-157X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?","name":"articletitle","label":"Article Title"},{"value":"Journal of Genetic Engineering and Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s43141-020-00055-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Academy of Scientific Research and Technology. Published by Elsevier BV.","name":"copyright","label":"Copyright"}],"article-number":"35"}}